ROCKET PHARMACEUTICALS, INC.
RCKTNasdaq
$3.44
↑ +0.9%Jul 17 close · end-of-day
Price
1Y↑ +20.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$385.7M
Enterprise Value
$241.4M
P/E
—
P/S
—
P/B
1.6
EV/EBITDA
—
PEG
—
FCF Yield
-46.6%
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$209.4M
Free Cash Flow (TTM)
-$179.8M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-88.0%
ROIC
-182.1%
Debt / Equity
—
Net Cash
$144.4M
Return 1Y
+3.0%
Company profile
Rocket Pharmaceuticals, Inc. focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells. The company also has a clinical stage in vitro virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure.
- CEO
- Gaurav D. Shah
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 240
- Headquarters
- New York
- Website
- rocketpharma.com
Management & directors
- Shah GauravCEO
- Militello JohnSee Remarks
- Wilson MartinGeneral Counsel
- Chaudhuri SarbaniSee Remarks
- Rizvi Syed Ali-AamirChief Medical Officer
- Stevens Christopher JamesChief Operating Officer
- Schwartz Jonathan DavidSee Remarks
- Ondrey AaronChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
RCKT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$0.42↓ -25.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$134.3M | -$167.2M | -$224.3M | -$259.7M | -$273.2M | -$231.7M |
| Net income | -$139.7M | -$169.1M | -$221.9M | -$245.6M | -$258.7M | -$223.1M |
| Diluted EPS | -$2.52 | -$2.67 | -$3.26 | -$2.92 | -$2.73 | -$2.01 |
| Operating cash flow | -$74.6M | -$121.2M | -$178.1M | -$194.9M | -$209.7M | -$190.0M |
| Free cash flow | -$95.2M | -$128.8M | -$186.5M | -$211.4M | -$215.6M | -$190.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$73.7M | -$69.4M | -$62.7M | -$64.4M | -$71.1M | -$52.2M | -$44.0M | -$48.5M |
| Net income | -$69.6M | -$66.7M | -$60.3M | -$61.3M | -$68.9M | -$50.3M | -$42.5M | -$47.6M |
| Diluted EPS | -$0.74 | -$0.71 | -$0.62 | -$0.56 | -$0.62 | -$0.45 | -$0.38 | -$0.42 |
| Operating cash flow | -$53.8M | -$52.1M | -$46.9M | -$55.8M | -$49.0M | -$50.4M | -$34.8M | -$45.4M |
| Free cash flow | -$55.8M | -$53.7M | -$47.3M | -$56.2M | -$49.0M | -$50.5M | -$34.9M | -$45.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 28, 2026
May 20, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-18 | Malik Fady Ibraham | Award | 22,862 | $0.00 | $0.00 | filing |
| 2026-06-18 | Fong Peter | Award | 22,862 | $0.00 | $0.00 | filing |
| 2026-06-18 | Dolsten Mikael | Award | 22,862 | $0.00 | $0.00 | filing |
| 2026-06-18 | WONG RODERICK | Award | 27,832 | $0.00 | $0.00 | filing |
| 2026-06-18 | SOUTHWELL DAVID P | Award | 22,862 | $0.00 | $0.00 | filing |
| 2026-06-18 | BOESS CARSTEN | Award | 22,862 | $0.00 | $0.00 | filing |
| 2026-05-21 | Shah Gaurav· CEO | Sale | 55,684 | $3.09 | $171,840.82 | filing |
| 2026-05-21 | Shah Gaurav· CEO | Option exercise | 76,490 | $1.69 | $129,344.59 | filing |
| 2026-05-19 | Shah Gaurav· CEO | Sale | 2,409 | $3.01 | $7,260.73 | filing |
| 2026-05-19 | Wilson Martin· General Counsel | Sale | 662 | $3.01 | $1,995.27 | filing |
| 2026-05-19 | Militello John· See Remarks | Sale | 384 | $3.01 | $1,157.38 | filing |
| 2026-05-13 | Wilson Martin· General Counsel | Sale | 3,361 | $3.61 | $12,119.77 | filing |
| 2026-05-13 | Shah Gaurav· CEO | Sale | 2,728 | $3.61 | $9,837.17 | filing |
| 2026-05-13 | Militello John· See Remarks | Sale | 855 | $3.61 | $3,083.13 | filing |
| 2026-05-07 | Chaudhuri Sarbani· See Remarks | Sale | 17,650 | $3.84 | $67,740.70 | filing |
| 2026-02-18 | Shah Gaurav· CEO | Sale | 5,990 | $3.34 | $19,994.62 | filing |
| 2026-02-18 | Wilson Martin· General Counsel | Sale | 1,376 | $3.34 | $4,593.09 | filing |
| 2026-02-18 | Militello John· See Remarks | Sale | 1,157 | $3.34 | $3,862.07 | filing |
| 2026-02-13 | Shah Gaurav· CEO | Sale | 12,279 | $3.31 | $40,668.05 | filing |
| 2026-02-13 | Wilson Martin· General Counsel | Sale | 12,253 | $3.31 | $40,581.94 | filing |
| 2026-02-13 | Militello John· See Remarks | Sale | 3,726 | $3.31 | $12,340.51 | filing |
| 2026-02-11 | Militello John· See Remarks | Award | 29,982 | $0.00 | $0.00 | filing |
| 2026-02-11 | Wilson Martin· General Counsel | Award | 311,813 | $0.00 | $0.00 | filing |
| 2026-02-11 | Rizvi Syed Ali-aamir· Chief Medical Officer | Award | 61,963 | $0.00 | $0.00 | filing |
| 2026-02-11 | Stevens Christopher James· Chief Operating Officer | Award | 61,963 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.